Health ProductsPublic Communication

Archived - Cialis (tadalafil), Levitra (vardenafil hydrochloride) and Viagra (sildenafil citrate) - Advisories, Warnings and Recalls for the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Drugs
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Eli Lilly Canada Inc., Bayer Inc. and Pfizer Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Public Communication - Health Canada Endorsed Important Safety Information on Cialis® (tadalafil), Levitra® (vardenafil hydrochloride) and Viagra® (sildenafil citrate)

June 19, 2006

Subject:Association of the erectile dysfunction medications Cialis® (tadalafil), Levitra® (vardenafil hydrochloride) and Viagra® (sildenafil citrate) with visual problems.

The manufacturers of Cialis®, Levitra® and Viagra®, following discussions with Health Canada, would like to inform you of important safety information regarding a very small number of reports of serious visual problems in patients taking these medications.

  • A very small number of men worldwide have reported visual problems and rarely lost eyesight in one eye after taking Cialis®, Levitra® or Viagra®.
  • It has not been established whether these visual problems are related directly to the use of these medications or to other factors.
  • If you are taking these medications and experience loss of vision, you should stop using the medication and have your eyes examined by a doctor as soon as possible.
  • People who previously experienced a type of vision loss called Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) may be at an increased risk of reoccurrence of NAION.

There have been rare reports of vision loss with the use of these erectile dysfunction medications. The vision loss may be partial or complete, affecting one or very rarely both eyes. While in some cases it may improve over time, it can also be irreversible. Those who experience one episode may be at greater risk of having a second episode in the other eye. The number of cases is small and most have occurred outside of Canada. As of October 31st, 2005, there have been 5 Canadian cases of visual problems that are possibly related to an erectile dysfunction medication.

Men who have erectile problems often have other conditions that put them at increased risk of NAION, including age greater than 50 years, heart disease, high blood pressure, high cholesterol, diabetes and certain pre-existing eye problems.

If you have questions about your current prescription, contact your physician or pharmacist.

A letter has been sent to Canadian physicians advising them of these safety information. This letter can be found on the Health Canada website at: (Health Canada's website ).

This communication follows the earlier advisory issued by Health Canada on July 26, 2005 on the same issue.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious visual problems or other serious or unexpected adverse reactions in patients receiving Cialis®, Levitra® or Viagra® should be reported to their respective manufacturers or Health Canada at the following addresses:

For CIALIS®:
Customer Response Centre Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, Ontario M1N 2E8
Tel: 1-888-545-5972
Fax: 1-888-898-2961

For LEVITRA®:
Drug Safety
Bayer Health Care
77 Belfield Road
Toronto, Ontario M9W 1G6
Tel: 1-800-265-7382
Fax: 1-866-232-0565

For VIAGRA®:
Pfizer Canada Inc.
Drug Safety
P.O. Box 800
Pointe-Claire-Dorval
Quebec, H9R 4V2
Tel: 1-800-463-6001
Fax: (514) 426-7529

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337
Fax: (613) 957-0335

To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime